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Abstract
This study compared the effects of adding acceptance and commitment therapy (ACT) or
exposure and response prevention (ERP) to adults diagnosed with obsessive compulsive disorder
(OCD) already on an optimal and stable dose of selective serotonin reuptake inhibitors (SSRIs).
Forty adults on SSRIs who were diagnosed with OCD participated in a randomized controlled
trial in Iran of 12 individual weekly sessions of either ACT+SSRI, ERP+SSRI, or continued
SSRI only. The results showed significant reductions in OCD symptom severity in ACT+SSRI
and ERP+SSRI conditions at posttreatment with significantly greater reductions in both
conditions compared to SSRI-only at follow-up. Additionally, psychological inflexibility and use
of thought control strategies significantly decreased in the ACT+SSRI condition at posttreatment
and follow-up compared to the ERP+SSRI and SSRI conditions. Both conditions led to
decreases in perceived importance of stop signals. Results provide cross-cultural support for the
treatment of OCD using ACT and ERP as adjuncts to SSRI and modest process of change
differences between ACT and ERP. Future directions and study limitations are discussed.
Keywords: Obsessive-compulsive disorder, Acceptance and commitment therapy,
Exposure and response prevention, Selective serotonin reuptake inhibitors, Psychological
flexibility
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A preliminary investigation of Acceptance and commitment therapy (ACT) versus exposure and
response prevention (ERP) for patients with obsessive-compulsive disorder on an optimal dose
of SSRIs: A randomized controlled trial in Iran
Obsessive-compulsive disorder (OCD) is defined by the presence of (a) obsessions,
recurrent, persistent, and intrusive thoughts, urges, or images that cause marked significant or
distress and/or (b) compulsions, ritualistic behaviors performed according to rigid rules or in
response to obsessions (American Psychiatric Association [APA], 2013). OCD is a chronic and
debilitating disorder with a 12-month prevalence of 2.1% and lifetime prevalence of 3.2% among
the population all over the world (Osland, Arnold, & Pringsheim, 2018). In the Iranian
population, the prevalence of OCD is reported to be 1.8% overall, and 0.7% and 2.8% among
males and females respectively (Mohammadi et al., 2004). Iran’s most common obsessions are
doubts and indecisiveness and the most common compulsion is washing (Ghassemzadeh et al.,
2002). Also, unacceptable thoughts (e.g., blasphemous thoughts) and symmetry are the most
prevalent obsessions and compulsions among Iranian males, whereas fear of contamination and
compulsive washing are higher among Iranian females, (Ghassemzadeh et al., 2002). OCD is
associated with distress and interference with work/academic, interpersonal, leisure functioning,
and low quality of life (Abramowitz et al., 2009).
ERP is considered the “gold standard” and first-line psychotherapy treatment for OCD as
it has been repeatedly demonstrated to be efficacious in clinical research and naturalistic settings
(Abramowitz, 2017; Foa & McLean, 2016). Recent meta-analyses show between-condition
effect sizes in the 1.18-1.39 range for ERP and similar CBTs for OCD (McKay et al., 2015;
Olatunji, Davis, Powers, & Smits, 2013; Öst et al., 2015), supporting their treatment utility.
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However, a meta-analysis found that approximately 50% of those who receive these treatments
are non-responders at posttreatment and follow-up (Loerinc et al., 2015).
With respect to pharmacological approaches, SSRIs (e.g., fluoxetine, sertraline,
paroxetine, fluvoxamine) are the first-line treatment for OCD (Grassi & Pallanti, 2018). Metaanalyses indicate SSRIs are superior to placebo for the treatment of OCD (Soomro, Altman,
Rajagopal, & Oakley-Browne, 2008). However, antidepressants alone are insufficient as only
10% of patients with OCD taking a SSRI experience full remission of symptoms; the typical
response is a reduction of 20-40% of OCD symptoms (Ballenger, 1999; Mancebo et al., 2006;
Math & Janardhan Reddy, 2007; Pigott & Seay, 1999). Additionally, SSRI use potentially results
in unpleasant side effects including suicidality, sexual dysfunction, and weight gain (Hirschfeld,
2003; Moret, Isaac, & Briley, 2009).
Consequently, standard SSRI treatment is often combined with psychotherapy to
maximize treatment gains. Research has examined SSRIs in combination with forms of CBT
with some success (Franklin, Abramowitz, Bux Jr, Zoellner, & Feeny, 2002; Kampman,
Keijsers, Hoogduin, & Verbraak, 2002; Simpson et al., 2008; Tenneij, van Megen, Denys, &
Westenberg, 2005). However, this combination is not effective for all patients; in one large metaanalysis, researchers reported 43% of patients had a clinically significant response to receiving
ERP and an antidepressant (Öst, Havnen, Hansen, & Kvale, 2015). Similarly, only a 41%
symptom reduction was reported by patients after receiving CBT with an SSRI in a randomized
controlled trial (Kampman, Keijsers, Hoogduin, & Verbraak, 2002). Furthermore, researchers
noted a dropout rate of 32% for the combination of ERP and antidepressants, indicating ERP and
SSRIs may not be a satisfactory treatment combination for all patients (Öst, Havnen, Hansen, &
Kvale, 2015). Given that ACT appears to be comparably effective to existing empirically
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supported treatments for various conditions (A-Tjak et al., 2015; Zemestani, Mozaffari, 2020),
including OCD (Twohig et al., 2018), examining the combination of ACT and SSRIs in parallel
fashion to research on ERP and SSRIs may provide insight into how different combinations of
psychotherapy and pharmacotherapy may be similarly or differentially helpful. Because ACT
emphasizes context over symptoms, it may provide a more encompassing treatment approach to
combine with SSRIs, allowing the client to develop skills for leading a meaningful life in the
face of OCD, any potential SSRI side effects, and more.
ACT is a modern CBT with growing empirical support for the treatment of OCD (Bluett,
Homan, Morrison, Levin, & Twohig, 2014; Twohig et al., 2018). ACT is an experiential and
contextual behavioral approach to psychotherapy in which emphasis is placed on the context and
function of internal experiences, rather than the content and frequency with which they occur
(Twohig, Woidneck, & Crosby, 2013). The hypothesized process of change in ACT is
psychological flexibility (Twohig, Vilardaga, Levin, & Hayes, 2015). Psychological flexibility is
defined as the ability to mindfully respond to inner experiences while acting consistently with
personal values (Hayes, Luoma, Bond, Masuda, & Lillis, 2006). Based on the findings of recent
meta-analyses, psychological inflexibility is significantly correlated with OCD symptoms (Bluett
et al., 2014; Haaland et al., 2017), and psychological flexibility predicted improvement in ACT
for OCD (Twohig, Vilardaga, Levin, & Hayes, 2015).
A growing body of research shows ACT and ACT-informed treatments effectively treat
OCD (Bluett et al., 2014; Twohig et al., 2018; Twohig, Vilardaga et al., 2015). In the first
randomized trial of ACT for OCD, ACT outperformed progressive relaxation training (PRT),
with response rates in the 55–65% range at post-treatment and 3-month follow-up (Twohig et al.,
2010). In addition, Twohig et al. (2018) found ERP and ACT+ERP both led to significant
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decreases in OCD symptoms, depression, psychological inflexibility, and obsessional beliefs at
posttreatment that were maintained at six-month follow-up. There was also clinically significant
change in 70% of ACT+ ERP and 68% of ERP at posttreatment, and 60% in ACT+ERP and
64% in ERP at follow-up, indicating both conditions in this study were effective treatments for
OCD (Twohig et al., 2018).
In Iranian mental healthcare systems, SSRIs are considered the first-line treatment for
OCD, due to the limited availability of psychotherapy, so most patients start off with a
pharmacological intervention (e.g., Sabahi, Sepehri, Mohsenbeigi, & Sepehri, 2014; Sayyah &
Rahim, 2018). Psychotherapy is then added to the treatment plan by referring patients to the
clinical psychologist if patients do not respond to medication alone. In the context of a mostly
Western-centric evidence base for the utility of combining SSRIs with CBT, it is worth
examining the effectiveness of adding psychotherapy to SSRIs in an Iranian sample because such
data will tell us if results replicate across cultures. This research question is particularly pertinent
given the structure of Iranian mental healthcare systems wherein patients with OCD receive
SSRIs almost by default, signifying considerable homogeneity in treatment options offered.
Identifying an evidence-based alternative like SSRIs in combination with a CBT for Iranian
patients may thus go a long way toward improving overall treatment response rates.
Research has already been done to evaluate OCD treatment approaches in Iran. One study
randomized patients diagnosed with OCD to ACT (n = 30), clomipramine (n = 30), or
ACT+clomipramine (n = 30; Baghooli, Dolatshahi, Mohammadkhani, Moshtagh, & Naziri,
2014). Individual data tracking showed decreases in OCD symptom severity and increases in
quality of life with no significant differences among conditions (Baghooli et al., 2014). In
another randomized controlled trial, 23 adults on an optimal dose of SSRI completed group ACT
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for OCD. Results showed group ACT+SSRI led to a significantly larger decrease in OCD and
depressive symptoms and a significantly larger increase in psychological flexibility than the
SSRI-only group (n = 23; Rohani et al., 2018). In addition, 69 adolescents who were on a stable
dose of SSRI were randomized to ACT (n = 22), CBT (n = 22), or continued SSRI for OCD (n =
25; Shabani et al., 2019). ACT and CBT outperformed the continued SSRI condition and were
equivalent in reducing OCD severity. However, ACT showed bigger changes in its hypothesized
change processes: psychological inflexibility, valued living, and mindfulness (Shabani et al.,
2019). On the whole, the current evidence in Iran suggests psychotherapy combined with SSRIs
may be superior to SSRI alone though it is unclear if specifically adding ACT to SSRI use
consistently improves outcomes. Thus, more work is needed to identify reliably effective
treatments for OCD.
In addition to determining treatment effectiveness, looking at processes of change
measures can help shape intervention development and refinement. This understanding can then
be used to inform theoretical models and their application. For example, ERP and ACT are
hypothesized to effect change in different ways, so we would expect ERP to shift its specific
change process (e.g., decreases in dysfunctional beliefs; Polman, Bouman, Van Hout, De Jong,
& Den Boer, 2010) more so than psychological inflexibility and vice versa for ACT.
For ACT, we would expect psychological inflexibility to decrease more so than for ERP.
Moreover, we would expect decreases in thought control strategies in ACT given the deliberate
approach of observing thoughts without reacting to them. However, given use of cognitive
reappraisal in ERP, thought control strategies may remain the same or increase in this group. A
metacognitive process related to OC symptoms is maladaptive subjective criteria for stopping
compulsions (i.e., stop signals; Myers, Fisher, & Wells, 2009; Myers et al., 2017). Given both
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ERP and ACT address compulsions⎯albeit using different strategies⎯we would expect
maladaptive stop signals to decrease in both groups. For example, patients who receive ERP
might formulate more realistic criteria for stopping rituals (e.g., checking lock once instead of
five times) whereas those who receive ACT might choose to stop rituals based on entirely new
criteria of values rather than rules or feelings (i.e., “I will stop washing my hands to be with my
family even though I do not feel perfectly clean”).
The present study investigated the relative effectiveness of ACT+SSRI, ERP+SSRI, and
continued SSRI among adults in Iran on a stable dose of SSRIs. In addition, to examine change
processes relevant to ACT and ERP, we included measures of psychological flexibility, thought
control strategies, and stop signals. We predicted ACT+SSRI and ERP+SSRI would reduce
OCD symptoms over continued SSRI use alone. We also predicted the ACT+SSRI condition
would increase psychological flexibility and decrease use of thought control strategies compared
to the other two conditions. Finally, we predicted both ACT+SSRI and ERP+SSRI would
decrease self-reported importance of internal stop signals.
Method
Participants
Participants were recruited from private and public outpatient mental health centers in
Sanandaj, Iran. Private outpatient centers include individual psychiatric and psychological clinics
and public outpatient centers including a public psychoneurological specialized clinic that was
part of a psychiatric hospital. Study information was provided to psychiatrists and clinicians in
these centers and they were encouraged to refer potentially eligible persons. Potential
participants who were interested were asked to complete an in-person baseline interview to
determine eligibility. All enrolled participants provided written informed consent. Informed
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consent procedures were implemented at the first contact with participants. Following informed
consent procedures, the Structured Clinical Interview for DSM-5 (SCID-5; First & Williams,
2016) was administered as the primary clinical diagnostic instrument. Following eligibility
assessment, participants provided demographic and other background information. In addition,
an assessment battery was completed by participants at pretreatment, posttreatment, and 3-month
follow-up (see Measures section).
All participants were on optimal target doses of fluoxetine (20-80 mg), fluvoxamine (50300 mg), clomipramine (150-250 mg), and sertraline (50-200 mg) for at least six months and
monitored by independent psychiatrists unaware of study aims. Medication dosages remained
constant throughout the study and participants received no other psychotropic medication.
Primary inclusion criteria included (1) receiving the optimal and stable dose of SSRI for at least
six months prior to and during the study, (2) meeting DSM-5 (American Psychiatric Association,
2013) criteria for OCD following stable medication; (3) scoring at least 16 on the Yale-Brown
Obsessive Compulsive Scale Self-Report (Y-BOCS-SR) following stable medication, (4) being
aged 18 years or older, and (5) having at least a high school education in order to meet the
literary requirements of treatment. Participants were excluded if they met diagnostic criteria for
other DSM-5 psychiatric disorders that necessitated priority treatment not provided by the study
including current diagnosis of psychotic disorders, bipolar disorder, active suicidal ideation,
current substance abuse or dependence, and any personality disorder. Participants were also
excluded if they had received any form of psychological treatment in the past year.
Forty adults who met study inclusion criteria and agreed to participate were randomized
to either ACT+SSRI (n = 13), ERP+SSRI (n = 12), or SSRI (n = 15). Randomization was
conducted by an independent assessor (EG) using computer-generated blocks of random
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numbers who had no involvement in recruitment or posttreatment assessments. When groups
were evenly balanced, pre-prepared blocked randomization lists were used to allocate
participants to each group. See Table 1 for participant baseline sociodemographic and clinical
characteristics and Figure 1 for the participant flowchart. Scores on all measures appear in Table
2 and are graphed in Figure 2.
Procedure
The method was based on a randomized controlled trial design using the Consolidated
Standards of Reporting Trials (CONSORT) guidelines (Schulz, Altman, & Moher, 2010). The
study was registered in Iran’s Clinical Trial Center coded as IRCT2017081335675N1 and all
study procedures were approved by the Kurdistan University of Medical Sciences' ethics
committee coded as IR.MUK.REC.1396.77. Data were gathered by volunteers who held a
master’s degree in clinical psychology, had no involvement in the intervention phase of the
study, and were blind to the intervention arm. From posttreatment to follow-up, none of the
participants received any other form of psychosocial intervention.
Continued SSRI management. The SSRI management condition consisted of continued
use of SSRIs at the same levels prior to entering the study. Clients continued to be monitored by
the mental health center's psychiatrists once a month for three months in 30-minute sessions.
Participants taking psychotropic medications were advised not to make any changes during the
active phase of their treatment. Medication adherence was assessed at each visit by verbal report
and by pill counts. No psychological treatment was provided during the trial period. Following
completion of the study, all participants in the SSRI management condition participated in the
same treatment provided to those in the ACT or ERP condition.
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Adjunctive Acceptance and Commitment Therapy (ACT). The participants in the
ACT condition received SSRI management in addition to 12 individual weekly 90-minute
sessions using an ACT treatment manual. Treatment rationale, model, objectives, and themes
followed the standard ACT treatment manual used by Twohig et al. (2010) and Twohig,
Vilardaga et al. (2015). Cultural adaptation of the treatment was based on results from empirical
studies (Rohani et al, 2018) as well as personal experiences of the therapists in treatment with
this population. The original manual includes 8 sessions, but for the current study the number
was increased to 12 sessions. Most patients in Iran have problems in terms of receiving
psychotherapy, so the number of sessions was increased to avoid non-attendance and resistance.
This general attitude towards mental health problems, OCD, and psychotherapy were discussed
during two of the therapy sessions.
All sessions had essential objectives that included reviewing homework assignments and
discussion of events between sessions, in-session exercises, and metaphors adapted to Iranian
culture. Each session had a central theme based on ACT theory. Themes included creative
hopelessness, control as the problem, self-as-context, defusion, contact with present moment,
committing to learning how to become aware of each moment, acceptance, values, and
committed action, integrating ACT practices into daily life. Sessions involved a variety of
experiential exercises, interspersed with discussions of the role of acceptance in psychological
flexibility. Out-of-session behavioral commitments involved engagement in previously avoided
but meaningful activities. Focus was on values and increasing psychological flexibility, not on
habituation. The goal of these commitments was not to reduce obsessions or anxiety levels;
rather they were presented as opportunities to engage in important life values while practicing
ACT skills (e.g., acceptance, defusion, present moment awareness) if private experiences arose
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that might interfere with valued actions. Participants were instructed to practice homework
assignments every day between sessions for approximately a half hour.
One example of a cultural adaption was the use of the “vasvaseye Sheytan” or “Satan
temptation” metaphor, in which the praying and approaching to God represents values, the
intrusive religious blasphemous thoughts (obsessions) are Satan temptations. This metaphor
likens the experience of religious obsessions to getting caught in the temptations of the Satan.
The client practices ignoring the Satan temptations in praying times and allowing them to pass
with mindfulness techniques. We also linked treatment to religion by discussing how avoidance
strategies like compulsions can lead to not praying or postponing prayers. In the ACT sessions
with these clients we told them that these avoidance strategies keep them from their values (the
approach to God). We also discussed how giving Satan attention only increases his interest in
you. During the praying, the client has the opportunity to do exposure practices and ignore the
temptations of Satan and just watch them with mindfulness techniques.
Adjunctive Exposure and Response Prevention (ERP). The ERP condition consisted
of SSRI management in addition to 12 individual weekly 90-minute sessions using an
established ERP treatment manual for OCD (Foa & Kozak, 2004; Foa, Yadin, & Lichner, 2012).
Sessions included information-gathering, psychoeducation about the cognitive-behavioral model
of OCD and rationale for ERP, monitoring obsessional triggers, developing hierarchies, teaching
anxiety (SUDS) ratings, and monitoring SUDS ratings during exposure tasks in-session and as
homework. ERP entailed prolonged exposure to obsessional cues that induced discomfort and
strict abstinence of ritualizing behavior until the discomfort abated (leading to habituation of
anxiety). Exposure proceeded in a hierarchical fashion and sessions was dedicated to developing
the exposure hierarchy and response prevention plan. Sessions also included in-session graduated
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exposure therapy (in vivo and imaginal exposure), the assignment of between-session exposure
practices, and instructions to refrain from rituals during and between sessions. Similar to the
ACT condition, participants in the ERP condition were instructed to practice exposure exercises
between sessions, upwards of 30 minutes daily. Participants were taught to monitor their
subjective distress during exposure trials and observe habituation within and between trials.
Therapist and treatment fidelity
All sessions were run by one trained master's-level clinical psychologist who had at least
two years of clinical experience. The therapist had a strong background in CBT and underwent
extensive training in delivering ACT and ERP for OCD, receiving certification prior to treating
study patients. Furthermore, the therapist received supervised training in delivering ACT and
ERP for OCD. All sessions were audiotaped and were reviewed weekly by a supervisor to
establish internal validity. At the end of each session, the supervisor and the therapist discussed
the contents of the sessions to ensure adherence to the ACT and ERP treatment protocols. The
adherence of intervention was under the supervision of one doctoral-level clinical psychologists
(MZ) with varying lengths of post-qualification experience and extensive experience in the
treatment of OCD.
Measures
All measures were administered in translated Persian format.
Structured Clinical Interview for DSM-5 (SCID-5; First & Williams, 2016). The SCID-5
is a semi-structured clinical interview for the diagnosis and assessment of psychological and
psychiatric disorders using the Diagnostic and Statistical Manual, 5th edition. The SCID-5 uses
modules to assess for conditions such as mood disorders, anxiety disorders, and obsessivecompulsive and related disorders. The SCID-5 has demonstrated good internal consistency (>
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.80), as well as excellent reliability and validity in diagnosis of severity of mental disorders
(Shankman et al., 2018).
Yale-Brown Obsessive-Compulsive Scale Self-Report (Y-BOCS-SR; Goodman et al.,
1989). The Y-BOCS-SR was used as a 10-item self-report scale for assessment of the severity of
OCD symptoms. The sum of all items yields a total score (range = 0–40), with scores of 16 or
greater generally denoting clinically significant levels of OCD symptoms. It has demonstrated
both good interrater reliability for the total score (rs between .80 and .97) and 2-week test–retest
reliability (between .81 and .97) and has shown excellent treatment sensitivity (Goodman et al.,
1989; Steketee, Frost, & Bogart, 1996). Previous research has supported the use of self-report YBOCS as a moderately effective alternative to the clinician-administered versions in clinical
samples (du Mortier et al., 2019; Hauschildt, Dar, Schröder, & Moritz, 2019). In the current
study, the internal consistency (Cronbach’s α) at pretreatment was .71.
Stop Signals Questionnaire (SSQ; Myers, Fisher, & Wells, 2009). The SSQ is a 12-item
self-report measure that evaluates the importance of a variety of stop signals, the metacognitive
cues an individual experiences when rituals have been sufficiently completed (Myers, Fisher, &
Wells, 2009). The questionnaire defines stop signals and presents a list of 12 of them. It asks
respondents to rate how important each of the signals is for stopping their rituals on a five-point
Likert scale (0=not at all important and 4=extremely important). Internal consistency for the
scale was good (α=.89) and corrected total item correlations ranged from .48 to .67. Three-month
test–retest reliability was acceptable with a coefficient of .63 (Myers et al., 2009). In the current
study, Cronbach's α at pretreatment was .78.
Acceptance and Action Questionnaire - II (AAQ-II; Bond et al., 2011). The AAQ-II is a
seven-item, seven-point Likert-type self-report measure of experiential avoidance/psychological
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inflexibility. The items reflect: (a) unwillingness to experience unwanted emotions and thoughts
and (b) the inability to be in the present moment and behave according to value-directed actions
when experiencing unwanted psychological events. Higher scores indicate greater psychological
inflexibility and lower scores reflect larger experiential willingness and ability to act in the
presence of difficult thoughts and feelings. Bond et al. (2011) reported good test-retest reliability
(r=.81) at a three-month interval and good internal consistency (α=.78 to 87). In the current
study, Cronbach's α at pretreatment was .82.
Thought Control Questionnaire (TCQ; Wells & Davies, 1994). The TCQ is a 30-item
self-report measure that assesses use of thought control strategies. This is a widely used measure
for obsessive-compulsive and anxiety-related disorders and has been shown to change as a result
of cognitive-behavioral interventions (Reynolds & Wells, 1999). The TCQ has demonstrated
good test–retest reliability (r=.83). In the current study, Cronbach's α at pretreatment was .74.
Statistical Analyses
Power. Significant differences in symptom severity between SSRI-only versus
ACT+SSRI (d = 1.02 compared to SSRI-only) and CBT+SSRI (d = 1.42 compared to SSRIonly) were detected in a previous clinical trial in Iran that used a similar intervention with a
sample that was on stable doses of SSRI (Shabani et al., 2019). We expected that the current
study would yield similarly large effect sizes, stipulating group sizes between 12 and 21 to detect
significant between-group differences at a power of 0.80 and alpha of 0.05 for two comparisons
(ACT+SSRI to SSRI-only and CBT+SSRI to SSRI-only). Thus, our study with 13 in the
ACT+SSRI group, 12 in the CBT+SSRI group, and 15 in the SSRI-only group should be
sufficiently powered to detect large differences in OCD severity between active conditions and
the SSRI-only control condition. Group differences between the two active conditions were not
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expected for OCD severity based on previous trials comparing ACT and other forms of CBT
(Arch et al., 2012; Twohig et al., 2018). Furthermore, the same study found significant
differences between their CBT+SSRI and ACT+SSRI conditions on the Action and Fusion
Questionnaire (psychological inflexibility measure for adolescents; Shabani et al., 2019). Thus,
our study should be adequately powered to detect group differences in change processes as well.
However, these power calculations are only a guide for current analyses because power
calculation for multilevel analyses, which increase power by using all available data, require
knowledge of random variances, which is typically impossible to determine a priori.
Multilevel analyses. Multilevel analyses were conducted in RStudio (RStudio Team,
2015) with R (R Core Team, 2018) using the following packages: lme4 (Bates, Maechler,
Bolker, & Walker, 2015), texreg (Leifeld, 2013), and cowplot (Wilke, 2018). Linear mixed
effects (i.e., multilevel) models were used to examine the effect of condition on outcomes over
time. The outcomes of interest were OCD symptom severity (Y-BOCS-SR), importance of stop
signals (SSQ), psychological inflexibility (AAQ-II), and use of thought control strategies (TCQ).
For each outcome, a series of nested models with increasing complexity were specified and
compared in terms of model fit using a 2-difference test based on the likelihood function. Three
models were tested for each outcome variable. The first model contained only time (measured in
three discrete values: pretreatment, posttreatment, follow-up) as a fixed effect. The second model
contained time and condition (ACT+SSRI, ERP+SSRI, SSRI-only) as independent fixed effects.
The third and final model tested added a time  condition interaction term to the second model.
All models included random intercepts for individual participants. Final models were estimated
using the maximum likelihood criterion. All coefficient p-values reported are based on the
Satterthwaite approximation to degrees of freedom. Power analyses were not conducted due to
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difficulty doing so for multilevel modeling without full information on parameters (e.g., intraindividual correlations; Hox, Moerbeek, & van de Schoot, 2017).
Correlations between change scores. We examined Pearson correlations between
changes in the hypothesized processes of change and changes in OCD symptom severity. There
are two possible patterns that would not contradict the role of the hypothesized processes of
change as actual processes of change: (1) changes in processes from pre- to posttreatment are
correlated with changes in symptoms from pre- to posttreatment and (2) changes in processes
from pre- to posttreatment are correlated with changes in symptoms from posttreatment to
follow-up. In the first pattern, we assume that process changes are closely linked to symptom
changes such that they would be correlated within the same time period, whereas, in the second
pattern, we assume that there is a lagged response from process changes to symptoms changes.
While positive results from these tests are insufficient to show that the hypothesized processes of
change caused improvement in symptoms (given that we did not experimentally manipulate the
process variables), negative results in both tests would provide disconfirming evidence and
suggest that the hypothesized processes of change did not influence symptoms.
Results
Multilevel Findings
For all outcome variables, the best-fitting model included the two-way time  condition
interaction term, indicating the trajectories of OCD symptom severity, importance of stop
signals, psychological inflexibility, and use of thought control strategies over time were
significantly different among conditions (see Figure 2). Coefficients from the respective bestfitting models are presented in Table 3. Effect sizes were calculated from raw data using Cohen’s
d with d = 0.2 reflecting a small effect size, 0.5 a medium effect size, and 0.8 a large effect size.
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OCD symptom severity. The ACT+SSRI and ERP+SSRI groups showed decreases in
OCD symptom severity from pretreatment to posttreatment with gains maintained at follow-up
whereas the SSRI group had a relatively stable trajectory over time (see Figure 2, Panel A).
Coefficients from the best-fitting model suggest the ERP+SSRI group outperformed the SSRI
group over time (see Table 3). In addition, the ACT+SSRI group reported less OCD severity at
follow-up than the ERP+SSRI group. The posttreatment effect size between ACT+SSRI and
SSRI-only was large, d= 2.70, and the follow-up effect size between ACT+SSRI and SSRI-only
was also large, d = 2.70. The posttreatment effect size between ERP+SSRI and SSRI-only was
large, d = 2.65, and the follow-up effect size between ERP+SSRI and SSRI-only was also large,
d = 2.64.
Importance of stop signals. The trajectories of importance of stop signals mirrored those
for OCD symptom severity in which the ACT+SSRI and ERP+SSRI groups showed bigger
decreases over time relative to the SSRI group (see Figure 2, Panel B). Furthermore, scores in
the ACT+SSRI and ERP+SSRI groups were maintained from posttreatment to follow-up. The
ERP+SSRI group showed more improvement than the SSRI group over time and the ACT+SSRI
group had lower SSQ scores than the ERP+SSRI group at follow-up. The posttreatment effect
size between ACT+SSRI and SSRI-only was large, d= 2.90, and the follow-up effect size
between ACT+SSRI and SSRI-only was also large, d = 3.29. The posttreatment effect size
between ERP+SSRI and SSRI-only was large, d = 2.01, and the follow-up effect size between
ERP+SSRI and SSRI-only was also large, d = 1.95
Psychological inflexibility. The ACT+SSRI group showed a bigger decrease in
psychological inflexibility over time than the decrease in the ERP+SSRI group, which in turn
demonstrated significantly more improvement over time than the SSRI group (see Figure 2,
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Panel C and Table 3). Scores in the SSRI group were most consistent over time compared to the
other two groups. In addition, whereas the ERP+SSRI group seemed to maintain levels of
psychological inflexibility from posttreatment to follow-up, the ACT+SSRI group appeared to
show further decreases in scores from posttreatment to follow-up. The posttreatment effect size
between ACT+SSRI and ERP-SSRI was large, d= 1.88, and the follow-up effect size between
ACT+SSRI and ERP+SSRI was also large, d = 3.17.
Use of thought control strategies. Only the ACT+SSRI group showed a decreasing
trend for TCQ scores from pretreatment to follow-up (see Figure 2, Panel D), which was
significantly different from the ERP+SSRI group. There was no significant difference in the
trajectories of TCQ scores between the ERP+SSRI and SSRI groups (see Table 3). Although
means increased over time in the ERP+SSRI condition, overlapping error bars within the group
suggest these changes were non-significant, indicating a consistent trajectory in this group. The
posttreatment effect size between ACT+SSRI and ERP+SSRI was large, d = 2.35, and the
follow-up effect size between ACT+SSRI and ERP+SSRI was also large, d = 2.71.
Correlations Between Change Scores
Contemporaneous correlations. Decreases in psychological inflexibility, use of thought
control strategies, and importance of stop signals from pre- to post-treatment were significantly
associated with a decrease in OCD symptom severity from pre- to posttreatment (AAQ: r = .83,
p < .001; TCQ: r = .45, p = .004; SSQ: r = .92, p < .001). That is, improvement in processes of
change was significantly correlated with improvement in symptoms within the same timeframe.
Lagged correlations. Decreases in psychological inflexibility, use of thought control
strategies, and importance of stop signals from pre- to post-treatment were not significantly
associated with a decrease in OCD symptom severity from posttreatment to follow-up (AAQ: r =
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.26, p < .830; TCQ: r = .09, p = .45; SSQ: r = .22, p = .168). That is, improvement in processes
of change during treatment was not significantly correlated with improvement in symptoms that
occurred after the end of treatment.
Discussion
This preliminary study compared ACT+SSRI, ERP+SSRI, and continued SSRI for the
treatment of adults with OCD. As predicted, results showed ACT+SSRI and ERP+SSRI were
both highly effective treatments for OCD with significantly larger reductions in OCD symptom
severity in both conditions compared to SSRI-only at posttreatment and follow-up. Specifically,
adding ACT and ERP resulted in greater than 50% reductions in OCD symptoms versus
marginal gains in continued SSRI. Only one participant dropped out across all conditions. The
average number of sessions attended for the ACT+SSRIs and ERP+SSRIs groups were 11.2 (SD
= 4.31) and 11.6 (SD = 4.27) respectively.
Findings suggest ACT and ERP are useful adjuncts to SSRIs for the treatment of OCD in
an Iranian sample. Hence, they could be reasonable additive options for clients with OCD
already on SSRIs, particularly in countries such as Iran where this study was conducted. This
study also shows the successful cross-cultural implementation of two versions of CBT for OCD:
ACT and ERP. This is important because it suggests both treatments can be disseminated and
implemented with high session completion and low drop out in countries different from where
they originated and with discrepant cultural characteristics. There is substantial research on the
effectiveness of ERP for OCD but the research on ACT as a treatment for OCD is limited. This
study adds to the literature showing ACT for OCD can be useful at levels similar to ERP. Given
the single dropout, this study also adds to literature supporting similar dropout rates for ERP as
compared to other treatments for OCD (e.g., Ong et al., 2016).
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We also investigated changes in hypothesized processes of change for the ACT+SSRI
and ERP+SSRI conditions: psychological inflexibility and thought control strategies
respectively. As expected, ACT+SSRI had a stronger effect on reducing psychological
inflexibility. Additionally, ACT+SSRI decreased use of thought control strategies whereas
ERP+SSRI increased use of thought control strategies. Finally, ACT+SSRI and ERP+SSRI were
both effective in reducing the perceived importance of experiencing certain stop signals (i.e.,
indicators a ritual has been sufficiently completed) before disengaging in rituals. Correlations
between change scores on process and the outcome measure were also supportive. These process
of change findings suggest ACT and ERP may have impacted different hypothesized processes
of change: ACT decreased psychological inflexibility whereas ERP decreased use of thought
control strategies). However, both conditions shifted the perceived importance of stop
signals⎯potentially an overlapping process of change.
In theory, ACT and ERP could share similar processes of change as both entail
interacting with fear-provoking stimuli in new ways (e.g., approach instead of avoid), focus on
changing behaviors (typically compulsions) that compromise quality of life, and identify specific
thoughts, feelings, and behaviors as part of an OCD case formulation. However, the therapies
diverge with respect to what they ask clients to do with those identified thoughts and feelings.
Research thus far has been mixed as to whether ACT and ERP truly differ in the process of
change variables they affect. For example, one ACT+ERP versus ERP study saw no differences
in process of change (Twohig et al., 2018), though this study heavily emphasized ERP in both
conditions. In contrast, another Iranian study comparing ACT+SSRI to ERP+SSRI for
adolescent OCD also found process of change differences between ACT and ERP in the
predicted direction (Shabani et al., 2019). Other studies have supported psychological flexibility
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as a key process of change in ACT for OCD (Rohani et al., 2018; Twohig, Vilardaga, et al.,
2015). Nonetheless, the specificity of psychological flexibility as a process of change in ACT is
unclear. That is, while ACT may shift psychological flexibility, other therapies may do so too
(Twohig et al., 2018).
In the present study, psychological inflexibility also decreased in the ERP+SSRI
condition albeit to a lesser extent than ACT+SSRI. One reason ERP could lead to increases in
psychological flexibility is its provision of opportunities to interact with previously avoided
stimuli in a different way (i.e., approach), expanding the individual’s behavioral repertoire⎯a
key component of psychological flexibility. Conversely, the differential changes in thought
control strategies over time supported distinct targets in ACT versus ERP. Namely, the
ACT+SSRI condition led to reductions in thought control strategies⎯consistent with the
acceptance-based approach of observing thoughts without reacting to them⎯whereas the
ERP+SSRI condition resulted in increases in thought control strategies⎯consistent with a
cognitive reappraisal approach in which the premise is thoughts can be changed with cognitive
effort.
At the same time, the observed changes in psychological inflexibility and thought control
strategies only show that the treatments affected different hypothesized processes of change (i.e.,
procedure shifted process), but they do not tell us whether those processes of change actually
functioned as such (i.e., process shifted outcome). While our change score correlation results
provided preliminary evidence that psychological inflexibility and thought control strategies may
be relevant processes of change in treatment for OCD, they are insufficient to confirm this
hypothesis given lack of experimental control over the process variables. The link between
treatment and process and that between process and outcome are important because they signal
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malleability and clinical relevance respectively (Hofmann & Hayes, 2018). For example, it is
possible that ACT decreased psychological inflexibility, but that treatment response was
ultimately not attributable to this change. Thus, establishing a causal link between decreases in
psychological inflexibility and thought control strategies and improvement in outcomes is also
needed to support their role as empirically grounded processes of change.
This study has a number of limitations. First, the relatively small number of participants
per group might have precluded detection of significant differences between the active
conditions. Future work with larger samples would provide more power to detect differences
between ACT+SSRI and ERP+SSRI if they exist. At the same time, that the current study found
significant differences over time between active conditions on the AAQ-II and TCQ suggesting
it was sufficiently powered to detect differences on these measures. Although there were only
differences between active groups at follow-up for the Y-BOCS-SR and SSQ (favoring the
ACT+SSRI group), which could be attributable to low power, it is also plausible both conditions
were equally effective with respect to these outcomes given other trials with larger sample sizes
have found few differences in symptom severity between ACT and other forms of CBT (Arch et
al., 2012; Craske et al., 2014; Twohig et al., 2018). Overall, we recognize that the small sample
size of the present study has significant limitations for generalizability, particularly considering
the diverse clinical presentations of OCD. Second, our outcome measures were based on selfreport, highlighting the need for multimethod assessment in future similar studies. In particular,
using the clinician-administered version of the Y-BOCS would increase reliability and validity of
results. Furthermore, the present study did not use measures on dysfunctional beliefs or other
ERP-related constructs. This limitation is especially important to consider given the utility of
assessing OCD symptoms from a variety of perspectives, particularly clinician-based interview
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measures that can provide a deeper understanding of symptoms and severity. Third, unmeasured
cultural variables might have confounded current findings. For example, Iran has a collectivistic
culture that reinforces conformity (Zemestani, Abbarini, & Castonguay, 2019), which could have
affected treatment adherence and survey item responses. Consequently, it is possible the positive
treatment response and low variability were partly a product of culturally specific behavior and
not entirely attributable to the interventions per se. In other words, culture might have been a
moderating influence on our results. Additionally, treatment acceptability or engagement should
be monitored in future studies to see if there are between-condition differences. As noted earlier,
acceptability was likely high given the low drop-out, but replication and formal assessment of
acceptability are needed to clarify which aspects of treatment might enhance its acceptability.
Lastly, only one therapist provided treatment in both conditions and the present study does not
conduct formal analyses of treatment fidelity for either condition. Future research should use
multiple therapists of varying backgrounds to increase generalizability of findings, as well as
fidelity measures. Lastly, we wanted to note that the SSRI-only group was lacking a comparable
psychotherapy “placebo.” It is possible that the differences between the active and control groups
can be attributed to this discrepancy and it is a topic worth addressing in future research,
Despite these limitations, this study provides preliminary support for the effectiveness of
ACT+SSRI for OCD and adds to the literature supporting the use of ERP in conjunction with
SSRIs for treating OCD. Additionally, this study was conducted in a Middle East country while
much of the ACT, ERP, and OCD literature arises from North America and Europe; therefore,
this study provides a diverse cultural application of ACT and ERP for the treatment of OCD.
While further research on ACT for OCD is warranted, these findings are particularly
encouraging and support the applicability and effectiveness of ACT in its standard form in other
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cultures. In sum, the results of this study provide preliminary cross-cultural support for both
ACT and ERP as treatments for OCD and as a successful adjunct to SSRIs.
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Table 1
Demographic and clinical characteristics of the study groups

Age: (years; M ± SD)
Sex: n (%)
Male
Female
Marital status
Married
Single
Educational level: n (%)
Master’s degree
High school diploma
High school
Employment status: n (%)
Unemployed
Free job
Government job
Comorbid diagnosis: n (%)
Major depressive disorder
Generalized anxiety disorder

ACT+
SSRIs
(n = 13)
35.69 (9.34)

ERP+
SSRIs
(n = 12)
36.12 (7.76)

SSRIs
(n = 15)
31.73 (7.81)

5 (38.0)
8 (61.5)

5 (41.7)
7 (58.3)

7 (46.7)
8 (53.3)

11 (84.6)
2 (15.4)

9 (75.0)
3 (25.0)

9 (60.0)
6 (40.0)

4 (30.8)
7 (53.8)
2 (15.4)

6 (50.0)
2 (16.7)
4 (33.3)

10 (66.7)
3 (20.0)
2 (13.3)

7 (53.8)
3 (23.1)
3 (23.1)

6 (50.0)
4 (33.3)
2 (16.7)

3 (20.0)
4 (26.7)
8 (53.3)

6 (46.1)
1 (7.7)

5 (41.6)
2 (16.7)

8 (53.3)
1 (6.6)

t or
χ2
1.14
0.19

0.33
0.91

2.17

0.32

3.26

0.64

0.38

0.47

2.62

0.51

p

Social anxiety disorder
0 (0)
3 (25.0)
1 (6.6)
Specific phobia
2 (15.4)
0 (0)
2 (13.3)
Psychotropic medication: n
1.07 0.39
(%)
Fluoxetine
3 (23.1)
4 (33.3)
5 (33.3)
Fluvoxamine
3 (23.1)
3 (25.0)
3 (20.0)
Clomipramine
1 (7.7)
2 (16.7)
3 (20.0)
Sertraline
6 (46.2)
3 (25.0)
4 (26.7)
Medication dosage:
138.46 (50.14)
129.16 (66.39) 126.1 (63.89)
0.15 0.85
(milligrams; M ± SD)
Medication duration:
11 (6.32)
10 (7.18)
11.5 (8.02)
1.10 0.43
(months; M ± SD)
Note. ACT = Acceptance and commitment therapy; ERP = exposure and response prevention;
SSRIs = selective serotonin reuptake inhibitors.
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Table 2
Means and Standard Deviations at Pre-treatment, Post-treatment, and Follow-Up by Condition

Measure

ACT+SSRIs
(n = 13)
Pre
Post

Follow

Pre

ERP+SSRIs
(n = 12)
Post
Follow

Pre

SSRIs
(n = 15)
Post
Follow

Y-BOCSSR

27.46
(3.97)

12.07
(2.81)

11.69
(2.32)

26.18
(3.84)

13.09
(1.92)

13.90
(1.81)

25.13
(4.80)

21.40
(3.99)

23.0
(4.51)

SSQ

27.38
(5.61)

10.07
(3.91)

10.15
(3.41)

28.0
(4.80)

12.81
(4.93)

14.18
(4.87)

25.80
(4.53)

22.33
(4.51)

23.40
(4.56)

AAQ-II

50.53
(5.81)

29.30
(2.35)

26.07
(2.43)

47.27
(6.0)

35.54
(4.05)

35.36
(3.35)

44.46
(6.09)

40.53
(4.50)

41.33
(5.30)

TCQ

65.0
(7.22)

58.92
(3.94)

57.84
(2.73)

66.81
(6.19)

70.0
(5.36)

68.81
(5.03)

66.40
(8.33)

72.46
(6.73)

72.46
(6.35)

SUDS

9.30
(0.75)

1.76
(043)

1.30
(0.48)

9.09
(1.04)

2.81
(0.75)

2.54
(0.75)

8.60
(1.05)

6.46
(1.40)

6.46
(1.55)

Note. Y-BOCS-SR = Yale-Brown Obsessive-Compulsive Questionnaire; SSQ = Stop Signals Questionnaire;
AAQ-II = Acceptance and Action Questionnaire - II; TCQ = Thought Control Questionnaire; SUDS =
Subjective Units of Distress Scale.
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Table 3
Coefficients for Best-Fitting Mixed Effects Models for Outcomes of Interest

Intercept
Time (Posta)
Time (Follow-upa)
Group (ERP+SSRIb)
Group (ACT+SSRIb)
Time (Posta)  Group (ERP+SSRIb)
Time (Follow-upa)  Group (ERP+SSRIb)
Time (Posta)  Group (ACT+SSRIb)
Time (Follow-upa)  Group (ACT+SSRIb)

BIC
Log likelihood
Number of observations
Number of participants
*
p < 0.05. ** p < 0.01. *** p < 0.001.
a
Reference level is pretreatment.
b
Reference level is ERP+SSRI.

Y-BOCS-SR
25.13***
(0.94)
-3.73***
(0.84)
-2.13*
(0.84)
1.70
(1.40)
2.33
(1.37)
-10.02***
(1.27)
-10.87***
(1.27)
-11.65***
(1.24)
-13.64***
(1.24)

SSQ
25.80***
(0.94)
-3.47***
(0.90)
-2.40**
(0.90)
2.53
(1.41)
1.58
(1.38)
-12.03***
(1.35)
-11.68***
(1.35)
-13.84***
(1.32)
-14.83***
(1.32)

AAQ-II
44.47***
(1.26)
-3.93***
(1.15)
-3.13**
(1.15)
4.20*
(1.89)
6.07**
(1.85)
-9.48***
(1.72)
-10.12***
(1.72)
-17.30***
(1.68)
-21.33***
(1.68)

TCQ
66.40***
(1.55)
6.07***
(1.39)
6.07***
(1.39)
0.18
(2.33)
-1.40
(2.28)
-2.90
(2.08)
-3.65
(2.08)
-12.14***
(2.04)
-13.22***
(2.04)

639.08
-293.21
120
40

647.07
-297.20
120
40

706.35
-326.84
120
40

750.72
-349.03
120
40
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Invited to participate (n = 100)
Excluded (n = 47):
Not meeting inclusion criteria (n = 10)
Not willing to continue SSRIs, SRIs
(n = 12)
Declined to participate (n = 25)
Assessed for eligibility (n = 53)

Randomized (n = 40)

Excluded (n = 13):
Illiterate (n = 5)
Personality disorder (n = 4)
Psychotic symptoms (n = 2)
Substance abuse/dependence (n = 2)

Allocated to ACT+SSRIs
(n = 13)

Allocated to ERP+SSRIs
(n = 12)

Allocated to SSRIs
(n = 15)

Lost to post (n = 1)
Completers (n = 12)

Lost to post (n = 0)
Completers (n = 12)

Lost to post (n = 0)
Completers (n = 15)

Figure 1. Participant flowchart.
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Figure 2. Plots of mean outcome scores over time by condition. This figure shows the
trajectories of mean scores (with standard error bars) for each experimental condition over the
course of the study for outcomes of interest: OCD symptom severity, importance of stop signals,
psychological inflexibility, and use of thought control strategies.

